Litcius/Paper detail

Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study

Lisa Licitra, Makoto Tahara, Kevin J. Harrington, M. Olivera Hurtado de Mendoza, Yi Guo, Sercan Aksoy, Min Fang, Bogdan Żurawski, Tibor Csőszi, Mikhail Klochikhin, Tainá B. Oliveira, Shunji Takahashi, Muh‐Hwa Yang, Paul Swiecicki, Karen O’Hara, John Paul Shen, Andrew Z. Wang, B. Gumuscu, K.C. Benjamin, Robert I. Haddad

2024International Journal of Radiation Oncology*Biology*Physics32 citationsDOI

Topics & Concepts

MedicineLenvatinibPembrolizumabHead and neck squamous-cell carcinomaOncologyInternal medicineHead and neck cancerHead and neckSurgeryImmunotherapyRadiation therapyCancerThyroid cancerCancer Immunotherapy and BiomarkersHead and Neck Cancer StudiesLung Cancer Treatments and Mutations
Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study | Litcius